TERN
Terns Pharmaceuticals Inc.
Company Overview
| Mkt Cap | $1.62B | Price | $45.00 |
| Volume | 6.88M | Change | -4.44% |
| P/E Ratio | -18.2 | Open | $46.98 |
| Revenue | -- | Prev Close | $47.09 |
| Net Income | $-88.9M | 52W Range | $1.87 - $48.26 |
| Div Yield | N/A | Target | $29.89 |
| Overall | 64 | Value | 50 |
| Quality | 52 | Technical | 91 |
No chart data available
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Latest News
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and TScan Therapeutics (TCRX)
Barclays Remains a Buy on Terns Pharmaceuticals (TERN)
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN) and Ironwood Pharma (IRWD)
Barclays Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TERN | $45.00 | -4.4% | 6.88M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Terns Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW